ABO-Incompatible Adult Living Donor Liver Transplantation in the Era of Rituximab: A Systematic Review and Meta-Analysis.

Dipesh Kumar YadavYong Fei HuaXueli BaiJianying LouRisheng QueShunling GaoYun ZhangJi WangQinfen XieMuhammad Ibrahim Alhadi EdooVikram Kumar ChutturghoonJianpeng Sheng

Published in: Gastroenterology research and practice (2019)

Our meta-analysis included studies comparing ABOi and ABOc ALDLT after the introduction of rituximab in a desensitization protocol for ABOi ALDLT. The results of ABOi ALDLT were comparable with those of ABOc ALDLT. However, biliary complications, CMV infection, and AMR remain a concern in the era of rituximab.

Keyphrases

diffuse large b cell lymphoma
systematic review
chronic lymphocytic leukemia
hodgkin lymphoma
case control
randomized controlled trial
meta analyses
risk factors